Skip to main content
KALA
NASDAQ Life Sciences

KALA BIO's Q2 10-Q Reveals Material Weakness, $7M Loan, and AI Platform License

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.9
Mkt Cap
$17.406M
52W Low
$0.59
52W High
$1,030
52W Position info
53% above low
Off High info
100% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

KALA sits 53% above its 52-week low of $0.59 on light trading volume (0.2× avg).

Summary

KALA BIO's Q2 10-Q discloses a material weakness in internal controls, a $7M loan critical to liquidity, and a new AI platform license. Cash is under $0.1M, with operations funded by loan collections.


Key Events · Earnings and Guidance · KALA

  • Material Weakness in Internal Controls

    A material weakness in internal control over financial reporting was disclosed, stemming from insufficient personnel following restructuring. As of June 30, 2026, the weakness remained unremediated, and disclosure controls were deemed not effective.

  • $7M Loan to Minglemint Solutions

    On February 9, 2026, KALA BIO extended a $7.0 million loan to Minglemint Solutions LLC, bearing 8% interest. A call notice for $1.0 million was delivered on August 14, 2026, with repayment expected by September 28, 2026.

  • Liquidity Dependent on Loan Collections

    Cash and cash equivalents stood at less than $0.1 million as of the report date. Management believes existing cash plus collections from the Minglemint note will fund operations through Q3 2027.

  • Younet AI Platform License

    The company entered into a license agreement for the Researgency AI platform, with an option to acquire Younet for $55 million. Initial cash fees were $80,000, with potential additional payments of $450,000.


Analysis · KALA · Life Sciences

The Q2 10-Q from KALA BIO uncovers a material weakness in internal controls that remains unremediated, a $7 million loan to Minglemint Solutions now serving as a key liquidity source, and a new AI platform license with a $55 million purchase option. With less than $0.1 million in cash, the company is relying on collections from the loan to fund operations through Q3 2027. These material weaknesses and liquidity dependencies pose significant governance and financial risks.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KALA was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.4M. The 52-week trading range was $0.59 to $1,030.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KALA - Latest Insights

KALA
Sep 29, 2026, 7:30 AM EDT
Source: TMX Newsfile
Importance Score:
8
Price at Filing: $0.474
Real-time Price: $0.1519 info
Change: -$0.3221 (-68%) info
Market Cap: $2.949M info
KALA
Sep 24, 2026, 4:10 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.5288
Real-time Price: $0.1519 info
Change: -$0.3769 (-71%) info
Market Cap: $2.949M info
KALA
Sep 11, 2026, 4:56 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.590
Real-time Price: $0.1519 info
Change: -$0.4381 (-74%) info
Market Cap: $2.949M info
KALA
Sep 03, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.538
Real-time Price: $0.1519 info
Change: -$0.3861 (-72%) info
Market Cap: $2.949M info
KALA
Aug 28, 2026, 6:45 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.795
Real-time Price: $0.1519 info
Change: -$0.6431 (-81%) info
Market Cap: $2.949M info